40 related articles for article (PubMed ID: 8623464)
1. Dermal microvascular injury in the human peripheral blood lymphocyte reconstituted-severe combined immunodeficient (HuPBL-SCID) mouse/skin allograft model is T cell mediated and inhibited by a combination of cyclosporine and rapamycin.
Murray AG; Schechner JS; Epperson DE; Sultan P; McNiff JM; Hughes CC; Lorber MI; Askenase PW; Pober JS
Am J Pathol; 1998 Aug; 153(2):627-38. PubMed ID: 9708821
[TBL] [Abstract][Full Text] [Related]
2. Novel approach for enhancing skin allograft survival by bioadhesive nanoparticles loaded with rapamycin.
Liu Y; Ouyang Y; Yu L; Wang P; Peng Z; Liu H; Zhao S; Wang H; Zhou Z; Deng Y; Liu Y; Xie J
Int J Pharm; 2024 Feb; 651():123742. PubMed ID: 38151102
[TBL] [Abstract][Full Text] [Related]
3. Incorporation of proteinase inhibitors into silk-based delivery devices for enhanced control of degradation and drug release.
Pritchard EM; Valentin T; Boison D; Kaplan DL
Biomaterials; 2011 Jan; 32(3):909-18. PubMed ID: 20950854
[TBL] [Abstract][Full Text] [Related]
4. Site-specific immunosuppression using a new formulation of topical cyclosporine A with polyethylene glycol-8 glyceryl caprylate/caprate.
Tran HS; Malli D; Chrzanowski FA; Puc MM; Matthews MS; Hewitt CW
J Surg Res; 1999 May; 83(2):136-40. PubMed ID: 10329107
[TBL] [Abstract][Full Text] [Related]
5. KRP-203, a novel synthetic immunosuppressant, prolongs graft survival and attenuates chronic rejection in rat skin and heart allografts.
Shimizu H; Takahashi M; Kaneko T; Murakami T; Hakamata Y; Kudou S; Kishi T; Fukuchi K; Iwanami S; Kuriyama K; Yasue T; Enosawa S; Matsumoto K; Takeyoshi I; Morishita Y; Kobayashi E
Circulation; 2005 Jan; 111(2):222-9. PubMed ID: 15642767
[TBL] [Abstract][Full Text] [Related]
6. Progressive change in tolerance mechanisms after withdrawing combination immunosuppression with cyclosporine and rapamycine or leflunomide.
Lin Y; Waer M
Transplant Proc; 1996 Dec; 28(6):3159. PubMed ID: 8962224
[No Abstract] [Full Text] [Related]
7. Use of genetically modified allograft to deliver local immunomodulatory molecule with minimal systemic toxicity in a rat model of allogeneic skin flap transplantation.
Fu S; Yang Y; Xiao B; Li Y; Yi CG; Xia W; Guo SZ
Transplant Proc; 2010 Nov; 42(9):3815-9. PubMed ID: 21094862
[TBL] [Abstract][Full Text] [Related]
8. Effect of single-dose rapamycin-based immunosuppression on the development of cardiac allograft vasculopathy.
Goggins WC; Fisher RA; Cohen DS; Tawes JW; Grimes MM
J Heart Lung Transplant; 1996 Aug; 15(8):790-5. PubMed ID: 8878761
[TBL] [Abstract][Full Text] [Related]
9. Overview of a 10-year experience on methods and compositions for inducing site-specific immunosuppression with topical immunosuppressants.
Hewitt CW; Black KS
Transplant Proc; 1996 Apr; 28(2):922-3. PubMed ID: 8623464
[TBL] [Abstract][Full Text] [Related]
10. Withdrawal of immunosuppression: implications for composite tissue allograft transplantation.
Hricik DE
Transplant Proc; 1998 Sep; 30(6):2721-3. PubMed ID: 9745554
[TBL] [Abstract][Full Text] [Related]
11. A comparative approach to topical cyclosporine therapy.
Williams DL
Eye (Lond); 1997; 11 ( Pt 4)():453-64. PubMed ID: 9425407
[TBL] [Abstract][Full Text] [Related]
12. Use of pharmacologic immunosuppression to augment the specific unresponsiveness (tolerance) to skin allografts induced by donor-specific bone marrow in antilymphocyte serum-treated mice: the unique effect of sirolimus.
Hale D; Gottschalk R; Maki T; Monaco AP
Transplant Proc; 1998 Aug; 30(5):2432-4. PubMed ID: 9723527
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
